1. Home
  2. RNTX vs MSAI Comparison

RNTX vs MSAI Comparison

Compare RNTX & MSAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNTX
  • MSAI
  • Stock Information
  • Founded
  • RNTX 2001
  • MSAI 1995
  • Country
  • RNTX United States
  • MSAI United States
  • Employees
  • RNTX N/A
  • MSAI N/A
  • Industry
  • RNTX Biotechnology: Pharmaceutical Preparations
  • MSAI
  • Sector
  • RNTX Health Care
  • MSAI
  • Exchange
  • RNTX Nasdaq
  • MSAI Nasdaq
  • Market Cap
  • RNTX 26.5M
  • MSAI 25.9M
  • IPO Year
  • RNTX N/A
  • MSAI N/A
  • Fundamental
  • Price
  • RNTX $1.34
  • MSAI $0.68
  • Analyst Decision
  • RNTX Hold
  • MSAI Strong Buy
  • Analyst Count
  • RNTX 1
  • MSAI 1
  • Target Price
  • RNTX N/A
  • MSAI $2.50
  • AVG Volume (30 Days)
  • RNTX 65.2K
  • MSAI 58.4K
  • Earning Date
  • RNTX 08-14-2025
  • MSAI 08-13-2025
  • Dividend Yield
  • RNTX N/A
  • MSAI N/A
  • EPS Growth
  • RNTX N/A
  • MSAI N/A
  • EPS
  • RNTX N/A
  • MSAI N/A
  • Revenue
  • RNTX N/A
  • MSAI $5,591,000.00
  • Revenue This Year
  • RNTX N/A
  • MSAI $66.87
  • Revenue Next Year
  • RNTX N/A
  • MSAI $81.01
  • P/E Ratio
  • RNTX N/A
  • MSAI N/A
  • Revenue Growth
  • RNTX N/A
  • MSAI N/A
  • 52 Week Low
  • RNTX $1.04
  • MSAI $0.52
  • 52 Week High
  • RNTX $4.40
  • MSAI $3.33
  • Technical
  • Relative Strength Index (RSI)
  • RNTX 49.84
  • MSAI 46.02
  • Support Level
  • RNTX $1.06
  • MSAI $0.71
  • Resistance Level
  • RNTX $1.21
  • MSAI $0.75
  • Average True Range (ATR)
  • RNTX 0.10
  • MSAI 0.05
  • MACD
  • RNTX 0.02
  • MSAI -0.01
  • Stochastic Oscillator
  • RNTX 66.67
  • MSAI 36.79

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

About MSAI Infrared Cameras Holdings Inc.

MultiSensor AI Holdings Inc build and deploy intelligent multi-sensing platforms incorporating edge and cloud software solutions that leverage artificial intelligence (AI). It is a provider of sensing systems built around high-resolution thermal imagers, visible and acoustic imagers, as well as vibration and laser spectroscopy sensors, that perceive and measure heat, sound, vibration, and gas in industrial assets and the surrounding environment, helping companies gain insight to protect and manage their most important assets and infrastructure. It also offers a wide range of form factors for its sensor devices, including, among other form factors, small to large handheld designs with built-in displays and controls, and fixed-mounted single- and multi-sensor camera sensor systems.

Share on Social Networks: